Fluoroquinolones may reduce the risk of myocardial infarction

Antibiotic treatment for infections of Chlamydia pneumoniae has been associated with protection against myocardial infarction, probably via a stabilizing effect on the cytoskeleton of endothelial cells and on chondrocytes in humans. Dr Herings et al from the Netherlands decided to test this association through a case-control study to see whether patients receiving antibiotics for Chlamydia pneumoniae infections were less likely to have been admitted for a first acute MI (JAMA 2000 284:2998-2999)

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Antibiotic treatment for infections of Chlamydia pneumoniae has been associated with protection against myocardial infarction, probably via a stabilizing effect on the cytoskeleton of endothelial cells and on chondrocytes in humans. Dr Herings et al from the Netherlands decided to test this association through a case-control study to see whether patients receiving antibiotics for Chlamydia pneumoniae infections were less likely to have been admitted for a first acute MI (JAMA 2000 284:2998-2999).

They identified 628 patients, aged 35 to 75, admitted with a first hospitalization for MI, studied their drug history, and compared them to 1615 matched controls. Only intake of high doses of fluoroquinolones was significantly associated with a lower risk of acute myocardial infarction. For those who took more than one course of fluoroquinolones, the odds ratio was 0.12 (95% CI, 0.02-0.94). For all other antibiotics, in particular tetracyclines and macrolides, no significant association was observed.

The authors ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Tudor Toma

    This person does not yet have a bio.
Share
A greyscale image of cells dividing.
March 2025, Issue 1

How Do Embryos Know How Fast to Develop

In mammals, intracellular clocks begin to tick within days of fertilization.

View this Issue
Discover the history, mechanics, and potential of PCR.

Become a PCR Pro

Integra Logo
Explore polypharmacology’s beneficial role in target-based drug discovery

Embracing Polypharmacology for Multipurpose Drug Targeting

Fortis Life Sciences
3D rendered cross section of influenza viruses, showing surface proteins on the outside and single stranded RNA inside the virus

Genetic Insights Break Infectious Pathogen Barriers

Thermo Fisher Logo
A photo of sample storage boxes in an ultra-low temperature freezer.

Navigating Cold Storage Solutions

PHCbi logo 

Products

The Scientist Placeholder Image

Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV

Stirling Ultracold

Meet the Upright ULT Built for Faster Recovery - Stirling VAULT100™

Stirling Ultracold logo
Chemidoc

ChemiDoc Go Imaging System ​

Bio-Rad
The Scientist Placeholder Image

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb